Skip to main content

CORRECTION article

Front. Oncol., 13 October 2022
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1028118

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience

This article is a correction to:

  1. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

    1. Read original article
Li-Ching Lin&#x;Li-Ching Lin1†Wen-Kuan Huang&#x;Wen-Kuan Huang2†Chueh-Chuan Yen,Chueh-Chuan Yen3,4Ching-Yao YangChing-Yao Yang5Meng-Ta SungMeng-Ta Sung6Natalie S.M. WongNatalie S.M. Wong7Daniel T. T. ChuaDaniel T. T. Chua8Sarah W. M. LeeSarah W. M. Lee9Jen-Shi ChenJen-Shi Chen2Chun-Nan Yeh*Chun-Nan Yeh1*
  • 1Department of Surgery and GIST Team, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan
  • 2Division of Hematology-Oncology, Department of Internal Medicine and GIST Team, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan
  • 3Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
  • 4National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan
  • 5Department of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
  • 6Department of Oncology, Mennonite Christian Hospital, Haulien, Taiwan
  • 7Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong SAR, China
  • 8Department of Medicine, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China
  • 9Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong SAR, China

A Corrigendum on
Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience

by Lin L-C, Huang W-K, Yen C-C, Yang C-Y, Sung M-T, Wong NSM, Chua DTT, Lee SWM, Chen J-S and Yeh C-N (2022) Front. Oncol. 12:883399. doi: 10.3389/fonc.2022.883399

In the published article, there was an error in affiliations 3 and 4. Instead of “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Taipei, Taiwan, 4 Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”, it should be “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, 4. National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”.

In the published article, an author name was incorrectly written as “Sean M.N. Wong”. The correct spelling is “Natalie S.M. Wong”.

In the published article, there was an error in the Funding statement. An acknowledgement was missed. The correct Funding statement appears below.

Funding

This work was supported in part by the Chang Gung Memorial Hospital CMRPG3J0971~3 CORPG3J0251~3. We thank to Zai Lab (Taiwan) Limited for the educational grant to Taiwan Society of Molecular Medicine. The funder Zai Lab (Taiwan) was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ripretinib, GIST, compassionate use, advanced, metastatic

Citation: Lin L-C, Huang W-K, Yen C-C, Yang C-Y, Sung M-T, Wong NSM, Chua DTT, Lee SWM, Chen J-S and Yeh C-N (2022) Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. Front. Oncol. 12:1028118. doi: 10.3389/fonc.2022.1028118

Received: 01 September 2022; Accepted: 06 September 2022;
Published: 13 October 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Lin, Huang, Yen, Yang, Sung, Wong, Chua, Lee, Chen and Yeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chun-Nan Yeh, eWVoY2h1bm5hbkBnbWFpbC5jb20=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.